Advertisement

Drug that mimics Viagra shows promise as Alzheimer's treatment

A clinician reviews a brain scan.
A clinician reviews a brain scan. -  Copyright  Business Wire via AP Photo
Copyright Business Wire via AP Photo
By Gabriela Galvin
Published on
Share Comments Add Euronews on Google
Share Close Button

Experts said the results are encouraging, but that more research is needed before the drug is offered to patients.

An experimental drug that mimics Viagra could help slow down Alzheimer’s disease, a new global study has found.

ADVERTISEMENT
ADVERTISEMENT

The drug, called AR1001, is taken as a once-daily tablet. In a late-stage clinical trial, AR1001 slowed cognitive decline and memory loss by 31% among 604 people with early Alzheimer’s disease who were not taking other treatments.

The results were not statistically significant in a wider group of Alzheimer’s patients who also took other drugs, according to AriBio, the South Korean company that makes AR1001.

Experts said the results are encouraging, but that more research is needed before AR1001 is offered to patients.

“These topline results are an exciting sign that we could have a totally new treatment for early Alzheimer’s disease that tackles its causes, not just its symptoms,” said Richard Oakley, associate director for research and innovation at Alzheimer’s Society.

Like the erectile dysfunction drug Viagra, AR1001 belongs to a class of drugs called PDE5 inhibitors. AR1001 works by relaxing blood vessels to increase blood flow to the brain — though Oakley cautioned against taking Viagra to try to treat Alzheimer’s.

“AR1001 is from the same family of medicines as Viagra, but it is being developed specifically for Alzheimer’s disease,” he said.

In the trial, which took place in 13 countries, most side effects were mild to moderate, including diarrhoea, falls and dizziness, AriBio said.

The study results were presented at the Clinical Trials on Alzheimer's Disease conference in the United States. AriBio said it plans to discuss the findings with the U.S. Food and Drug Administration (FDA).

Alzheimer’s is the most common form of dementia, which affects 57 million people worldwide. There is currently no cure, prompting researchers to search for treatments to slow the progression of the disease.

“We look forward to seeing the full results from this trial and how this drug progresses,” Oakley said.

Go to accessibility shortcuts
Share Comments Add Euronews on Google

Read more